COVID-19 vaccination challenges: A mini-review

Abstract

The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses.

The Impact of Vaccination on COVID-19 Burden of Disease in the Adult and Elderly Population: A Systematic Review of Italian Evidence

“…In response to the pandemic, numerous containment and mitigation interventions have been put in place to prevent overwhelming healthcare systems and protect vulnerable populations [ 7 ]. Measures, such as social distancing, hand hygiene, masks, quarantines, and lockdowns, have proven effective in reducing SARS-CoV-2 transmission, but vaccination has also played a crucial role in minimizing the risk of serious illnesses from COVID-19 [ 3 , 8 , 9 , 10 , 11 ].…”

De vacunas y adyuvantes: los guerreros que nos protegen de infecciones

“…Gracias a los avances en la investigación en vacunas que se habían acumulado en los años previos a la pandemia fue posible el desarrollo, en un tiempo récord, de vacunas clásicas y de nueva generación, esto es, vacunas de virus inactivado, de rna (ácido ribonucleico), asociadas con vectores virales y, más recientemente, basadas en dna (ácido desoxirribonucleico) y proteínas recombinantes (Mohseni Afshar et al, 2022). Este logro, aunado a la prontitud de la aprobación para su uso en emergencias, redujo drásticamente la mortalidad por covid-19 y nos permitió restablecer progresivamente nuestras actividades, hasta alcanzar niveles comparables con los previos a la pandemia.…”

Novel antioxidant protein target therapy to counter the prevalence and severity of SARS-CoV-2

“…It has been previously found that mutations induced in the spike protein are chiefly responsible for dampening the effects of vaccines which remain effective for various strains but are most effective for the original strain against which they were made. Thus, it causes a need for booster doses ( 105 ).…”